- Home
- CASI vs EQ Comparison
CASI vs EQ Comparison
Compare CASI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- EQ
- Stock Information
- Founded
- CASI 1991
- EQ 2017
- Country
- CASI China
- EQ United States
- Employees
- CASI N/A
- EQ N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- EQ Health Care
- Exchange
- CASI Nasdaq
- EQ Nasdaq
- Market Cap
- CASI 35.0M
- EQ 31.1M
- IPO Year
- CASI 1996
- EQ 2018
- Fundamental
- Price
- CASI $2.21
- EQ $0.74
- Analyst Decision
- CASI Strong Buy
- EQ Buy
- Analyst Count
- CASI 1
- EQ 2
- Target Price
- CASI $6.00
- EQ $5.00
- AVG Volume (30 Days)
- CASI 8.1K
- EQ 130.5K
- Earning Date
- CASI 03-27-2025
- EQ 03-24-2025
- Dividend Yield
- CASI N/A
- EQ N/A
- EPS Growth
- CASI N/A
- EQ N/A
- EPS
- CASI N/A
- EQ N/A
- Revenue
- CASI $22,055,000.00
- EQ $45,914,000.00
- Revenue This Year
- CASI N/A
- EQ $4.77
- Revenue Next Year
- CASI $134.79
- EQ N/A
- P/E Ratio
- CASI N/A
- EQ N/A
- Revenue Growth
- CASI N/A
- EQ 7.70
- 52 Week Low
- CASI $2.04
- EQ $0.49
- 52 Week High
- CASI $7.67
- EQ $2.99
- Technical
- Relative Strength Index (RSI)
- CASI 35.91
- EQ 45.33
- Support Level
- CASI $2.15
- EQ $0.66
- Resistance Level
- CASI $2.49
- EQ $0.87
- Average True Range (ATR)
- CASI 0.15
- EQ 0.07
- MACD
- CASI 0.00
- EQ -0.01
- Stochastic Oscillator
- CASI 35.42
- EQ 32.46
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.